CN106470986A - 环己烯‑1‑基‑吡啶‑2‑基‑1h‑吡唑‑4‑甲酸衍生物及其作为可溶性鸟苷酸环化酶激活剂的用途 - Google Patents
环己烯‑1‑基‑吡啶‑2‑基‑1h‑吡唑‑4‑甲酸衍生物及其作为可溶性鸟苷酸环化酶激活剂的用途 Download PDFInfo
- Publication number
- CN106470986A CN106470986A CN201580036309.9A CN201580036309A CN106470986A CN 106470986 A CN106470986 A CN 106470986A CN 201580036309 A CN201580036309 A CN 201580036309A CN 106470986 A CN106470986 A CN 106470986A
- Authority
- CN
- China
- Prior art keywords
- methyl
- ethyl
- alkyl
- hydrogen
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCOC(c1c(*=C)[n](-c2cccc(/C(/CC(*)(*(C)C3)F)=C(\CO)/C(*)(*)*3N)*2C)nc1)=O Chemical compound CCOC(c1c(*=C)[n](-c2cccc(/C(/CC(*)(*(C)C3)F)=C(\CO)/C(*)(*)*3N)*2C)nc1)=O 0.000 description 3
- UXGMMCYDWTVOGD-UHFFFAOYSA-N CC(C)(C)[Si+](C)(C)OCC(C(C)(C)CCC1)=C1OS(C(C)(F)F)(=O)=O Chemical compound CC(C)(C)[Si+](C)(C)OCC(C(C)(C)CCC1)=C1OS(C(C)(F)F)(=O)=O UXGMMCYDWTVOGD-UHFFFAOYSA-N 0.000 description 1
- LVRRGMFLSBNYAV-UHFFFAOYSA-N CC(C)(CCC1)C(C(OC)=O)C1=O Chemical compound CC(C)(CCC1)C(C(OC)=O)C1=O LVRRGMFLSBNYAV-UHFFFAOYSA-N 0.000 description 1
- WQNDLSUVVJWIBL-UHFFFAOYSA-N CC(CCC1)C(CO)=C1c1cccc(-[n]2ncc(C(OC)=N)c2C(F)(F)F)n1 Chemical compound CC(CCC1)C(CO)=C1c1cccc(-[n]2ncc(C(OC)=N)c2C(F)(F)F)n1 WQNDLSUVVJWIBL-UHFFFAOYSA-N 0.000 description 1
- WURRWPGJZJPZPA-UHFFFAOYSA-N CCOC(c1c(C(F)(F)F)[n](-c2nc(C3=C(CO)C(C)(C)CCC3)ccc2)nc1)=O Chemical compound CCOC(c1c(C(F)(F)F)[n](-c2nc(C3=C(CO)C(C)(C)CCC3)ccc2)nc1)=O WURRWPGJZJPZPA-UHFFFAOYSA-N 0.000 description 1
- JGGASCOAXIUKMU-UHFFFAOYSA-N CCOC(c1c(C(F)(F)F)[n](-c2nc(C3=C(CO[Si+](C)(C)C(C)(C)C)C(C)CCC3)ccc2)nc1)=O Chemical compound CCOC(c1c(C(F)(F)F)[n](-c2nc(C3=C(CO[Si+](C)(C)C(C)(C)C)C(C)CCC3)ccc2)nc1)=O JGGASCOAXIUKMU-UHFFFAOYSA-N 0.000 description 1
- YLBGVSFXHDBJMD-UHFFFAOYSA-N CCOC(c1c(C(F)(F)F)[n](-c2nc(C3=C(COc4ccc(C5CCNCC5)cc4C)CCCC3)ccc2)nc1)=O Chemical compound CCOC(c1c(C(F)(F)F)[n](-c2nc(C3=C(COc4ccc(C5CCNCC5)cc4C)CCCC3)ccc2)nc1)=O YLBGVSFXHDBJMD-UHFFFAOYSA-N 0.000 description 1
- ZOGNZIGQBOOKFH-UHFFFAOYSA-N CCOCc1c(C(F)(F)F)[n](-c2nc(C3=C(COc4ccc(C(CC5)CCN5C(OC(C)(C)C)=O)cc4C)CCC3)ccc2)nc1 Chemical compound CCOCc1c(C(F)(F)F)[n](-c2nc(C3=C(COc4ccc(C(CC5)CCN5C(OC(C)(C)C)=O)cc4C)CCC3)ccc2)nc1 ZOGNZIGQBOOKFH-UHFFFAOYSA-N 0.000 description 1
- BMHLJHUAUFHECP-UHFFFAOYSA-N CCc([n](-c1nc(Br)ccc1)nc1)c1C(OCC)=N Chemical compound CCc([n](-c1nc(Br)ccc1)nc1)c1C(OCC)=N BMHLJHUAUFHECP-UHFFFAOYSA-N 0.000 description 1
- WTYAKMLUSOBDNP-UHFFFAOYSA-N CCc([n](-c1nc(C2=C(COc3ccc(C4CCNCC4)c(CC)c3)C(C)CCC2)ccc1)nc1)c1C(OCC)=C Chemical compound CCc([n](-c1nc(C2=C(COc3ccc(C4CCNCC4)c(CC)c3)C(C)CCC2)ccc1)nc1)c1C(OCC)=C WTYAKMLUSOBDNP-UHFFFAOYSA-N 0.000 description 1
- MSHJTWSUNMQKCI-UHFFFAOYSA-N CCc1cc(OCC(C(C)(C)CCC2)=C2c2cccc(-[n]3ncc(C(OCC)=O)c3C(F)(F)F)n2)ccc1C(CC1)CCN1C(C1CC1)=O Chemical compound CCc1cc(OCC(C(C)(C)CCC2)=C2c2cccc(-[n]3ncc(C(OCC)=O)c3C(F)(F)F)n2)ccc1C(CC1)CCN1C(C1CC1)=O MSHJTWSUNMQKCI-UHFFFAOYSA-N 0.000 description 1
- WGHDZXSKJPEPMY-UHFFFAOYSA-N CCc1cc(OCC(C(C)CCC2)=C2c2cccc(-[n]3ncc(C(O)=O)c3C(F)F)n2)ccc1C(CC1)CCN1C(C1CC1)=O Chemical compound CCc1cc(OCC(C(C)CCC2)=C2c2cccc(-[n]3ncc(C(O)=O)c3C(F)F)n2)ccc1C(CC1)CCN1C(C1CC1)=O WGHDZXSKJPEPMY-UHFFFAOYSA-N 0.000 description 1
- FNEBNVRWTSBLMP-UHFFFAOYSA-N CCc1cc(OCC(C(C)CCC2)=C2c2cccc(-[n]3ncc(C(O)=O)c3C)n2)ccc1C(CC1)CCN1C(C1CC1)=O Chemical compound CCc1cc(OCC(C(C)CCC2)=C2c2cccc(-[n]3ncc(C(O)=O)c3C)n2)ccc1C(CC1)CCN1C(C1CC1)=O FNEBNVRWTSBLMP-UHFFFAOYSA-N 0.000 description 1
- RMJUZJQMBKKGFC-UHFFFAOYSA-N Cc(cc(C(CC1)CCN1C(C1CC1)=O)cc1)c1OCC(CCCC1)=C1c1cccc(-[n]2ncc(C(O)=O)c2C(F)(F)F)n1 Chemical compound Cc(cc(C(CC1)CCN1C(C1CC1)=O)cc1)c1OCC(CCCC1)=C1c1cccc(-[n]2ncc(C(O)=O)c2C(F)(F)F)n1 RMJUZJQMBKKGFC-UHFFFAOYSA-N 0.000 description 1
- REDLGFOCFUMDOP-UHFFFAOYSA-N Cc1cc(C(CC2)=CCN2C(C2CC2)=C)ccc1[N+]([O-])=O Chemical compound Cc1cc(C(CC2)=CCN2C(C2CC2)=C)ccc1[N+]([O-])=O REDLGFOCFUMDOP-UHFFFAOYSA-N 0.000 description 1
- PQARDSOLYLHRQD-UHFFFAOYSA-N Cc1cc(C2CCNCC2)ccc1O Chemical compound Cc1cc(C2CCNCC2)ccc1O PQARDSOLYLHRQD-UHFFFAOYSA-N 0.000 description 1
- SXWYZAOBWLVQAL-UHFFFAOYSA-N Nc1ccc(C(CC2)CCN2C(C2CC2)=N)cc1 Chemical compound Nc1ccc(C(CC2)CCN2C(C2CC2)=N)cc1 SXWYZAOBWLVQAL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462020187P | 2014-07-02 | 2014-07-02 | |
| US62/020,187 | 2014-07-02 | ||
| US201562127535P | 2015-03-03 | 2015-03-03 | |
| US62/127,535 | 2015-03-03 | ||
| US201562168651P | 2015-05-29 | 2015-05-29 | |
| US62/168,651 | 2015-05-29 | ||
| PCT/IB2015/055009 WO2016001878A1 (en) | 2014-07-02 | 2015-07-02 | Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106470986A true CN106470986A (zh) | 2017-03-01 |
Family
ID=53724404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580036309.9A Pending CN106470986A (zh) | 2014-07-02 | 2015-07-02 | 环己烯‑1‑基‑吡啶‑2‑基‑1h‑吡唑‑4‑甲酸衍生物及其作为可溶性鸟苷酸环化酶激活剂的用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9957254B2 (https=) |
| EP (1) | EP3164396B1 (https=) |
| JP (1) | JP2017519836A (https=) |
| CN (1) | CN106470986A (https=) |
| TW (1) | TW201625586A (https=) |
| WO (1) | WO2016001878A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201625584A (zh) | 2014-07-02 | 2016-07-16 | 諾華公司 | 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途 |
| US10364256B2 (en) | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| US10351530B2 (en) * | 2015-10-06 | 2019-07-16 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as NRF2 regulators |
| JP2018537488A (ja) | 2015-12-18 | 2018-12-20 | ノバルティス アーゲー | インダン誘導体、ならびに可溶性グアニル酸シクラーゼ活性化剤としてのその使用 |
| RU2019104002A (ru) * | 2016-07-22 | 2020-08-24 | Тоа Эйо Лтд. | Терапевтическое средство от глаукомы |
| CA3039735A1 (en) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| JP7314173B2 (ja) | 2018-04-30 | 2023-07-25 | バイエル アクチェンゲゼルシャフト | 認知障害の治療のためのｓＧＣ活性化薬及びｓＧＣ刺激薬の使用 |
| CA3100096A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| EP3574905A1 (en) | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
| EP3911675A1 (en) | 2019-01-17 | 2021-11-24 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc) |
| EP4536205A1 (en) | 2022-06-09 | 2025-04-16 | Bayer Aktiengesellschaft | Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101939053A (zh) * | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CN102414194A (zh) * | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1332943C (zh) | 1998-07-08 | 2007-08-22 | 萨诺费－阿文蒂斯德国有限公司 | 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂 |
| EP1420023B1 (en) | 2001-01-24 | 2006-12-06 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Use of fused pyrazolyl compounds for the preparation of a medicament for treating hypertension |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| CA2672212A1 (en) | 2006-12-11 | 2008-06-19 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
| DE102007015035A1 (de) | 2007-03-29 | 2008-10-02 | Bayer Healthcare Ag | Substituierte Dibenzoesäure-Derivate und ihre Verwendung |
| WO2009068652A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators |
| PE20091258A1 (es) | 2007-12-03 | 2009-09-12 | Smithkline Beecham Corp | Derivados de piridina como activadores de la guanilato ciclasa soluble |
| CN102056907B (zh) | 2008-04-04 | 2014-12-31 | 武田药品工业株式会社 | 杂环衍生物及其用途 |
| DE102008018675A1 (de) | 2008-04-14 | 2009-10-15 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Carbonsäure-Derivate und ihre Verwendung |
| DE102009012314A1 (de) | 2009-03-09 | 2010-09-16 | Bayer Schering Pharma Aktiengesellschaft | Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung |
| DE102009046115A1 (de) | 2009-10-28 | 2011-09-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 3-Phenylpropansäuren und ihre Verwendung |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| WO2012076466A2 (de) | 2010-12-07 | 2012-06-14 | Bayer Pharma Aktiengesellschaft | Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung |
| JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| JP5826393B2 (ja) | 2011-08-12 | 2015-12-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| JP5565645B1 (ja) | 2012-10-09 | 2014-08-06 | Ｄｉｃ株式会社 | バンプクッション |
| EP3024455A1 (en) | 2013-07-25 | 2016-06-01 | Bayer Pharma Aktiengesellschaft | Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis |
| JP2016530292A (ja) | 2013-09-05 | 2016-09-29 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 新規な可溶性グアニル酸シクラーゼ活性剤およびそれらの使用 |
-
2015
- 2015-07-01 TW TW104121396A patent/TW201625586A/zh unknown
- 2015-07-02 US US15/320,815 patent/US9957254B2/en active Active
- 2015-07-02 EP EP15742105.8A patent/EP3164396B1/en not_active Not-in-force
- 2015-07-02 JP JP2017520036A patent/JP2017519836A/ja not_active Ceased
- 2015-07-02 WO PCT/IB2015/055009 patent/WO2016001878A1/en not_active Ceased
- 2015-07-02 CN CN201580036309.9A patent/CN106470986A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101939053A (zh) * | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| CN102414194A (zh) * | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016001878A1 (en) | 2016-01-07 |
| EP3164396B1 (en) | 2019-01-16 |
| US20170197941A1 (en) | 2017-07-13 |
| EP3164396A1 (en) | 2017-05-10 |
| TW201625586A (zh) | 2016-07-16 |
| JP2017519836A (ja) | 2017-07-20 |
| US9957254B2 (en) | 2018-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106470986A (zh) | 环己烯‑1‑基‑吡啶‑2‑基‑1h‑吡唑‑4‑甲酸衍生物及其作为可溶性鸟苷酸环化酶激活剂的用途 | |
| US10550102B2 (en) | Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators | |
| US9765067B2 (en) | Thiophen-2-yl-pyridin-2-yl-1H-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | |
| CN105229003B (zh) | 作为补体因子b抑制剂用于治疗眼科疾病的2‑(1h‑吲哚‑4‑基甲基)‑3h‑咪唑并[4,5‑b]吡啶‑6‑甲腈衍生物 | |
| TWI577677B (zh) | 作爲ｔｔｘ－ｓ阻斷劑之吡咯並吡啶酮衍生物 | |
| CN106458994A (zh) | 联芳激酶抑制剂 | |
| CN105849090A (zh) | 2-苄基-苯并咪唑补体因子b抑制剂及其用途 | |
| CN115413279A (zh) | P2x3调节剂 | |
| US10316020B2 (en) | Indane derivatives and the use thereof as soluble guanylate cyclase activators | |
| CN107108552A (zh) | 杂环激酶抑制剂 | |
| CN111434653A (zh) | 三氮唑类化合物及其制备方法与用途 | |
| WO2025001956A1 (zh) | 杂芳族甲酰胺类化合物及其在医药上的应用 | |
| HK40041775B (zh) | 三氮唑类化合物及其制备方法与用途 | |
| CN106674207A (zh) | 取代的芳基杂芳基化合物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170301 |